Merck & Co's Viralytics Buy Puts Oncolytic Viruses Back In Spotlight

 
• By Kevin Grogan
Merry-go-round
All aboard: Merck & Co is the latest big pharma to take part in M&A this year • Source: Shutterstock

More from Immuno-oncology

More from Anticancer